Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy

PR Newswire

VANCOUVER, BC, Dec. 16, 2025

Issued on behalf of Avant Technologies Inc.

(OTCQB: BCLI).Avant Technologies, Inc.ProKidney Corp.Mesoblast LimitedLineage Cell Therapeutics, Inc.BrainStorm Cell Therapeutics Inc.VANCOUVER, BCDec. 16, 2025^[1]^[2]

The regenerative medicine market is projected to surge from $48.45 billion in 2024 to $403.86 billion by 2032, with cell-based therapies representing the fastest-growing segment, yet most emerging biotechs trade at steep discounts to this trajectory^[3]^[4]

, the company is advancing a proprietary differentiation process achieving high-efficiency conversion of stem cells into insulin-producing and regulating cells, targeting type 1 and insulin-dependent type 2 diabetes patients globally. This innovative approach addresses a fundamental challenge: the immune system's rejection of implanted cells, which historically required lifelong immunosuppressive drugs carrying significant risks.highlighted the critical roleAvant Technologies, Inc.Insulinova, Inc.SGAustria Pte. Ltd.

"Cell encapsulation is a game-changer in the field of regenerative medicine," said Chris Winter, CEO ofAvant TechnologiesSGAustria

The market opportunity is substantial. According to the International Diabetes Federation, 589 million people globally live with both type 1 and insulin-dependent type 2 diabetes, projected to reach 853 million by 2050, a 46% increase.SGAustria'sAvant

therapies.anti-agingAvant'sKlothonovaAustrianovaJournal of the American Heart Association

Bothover 50 peer-reviewed publications $32.8 billion by 2033 leading cause of death 850 million people worldwideSGAustriaAustrianovaAvant

https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/CONTINUED... Read this and more news for Avant Technologies at:

receptor agonists.recently presentedProKidney Corp.GLP-1

"The Phase 2 REGEN-007 full results recently presented at ASN Kidney Week further strengthen the body of evidence supporting our ongoing Phase 3 PROACT 1 study and underscore the potential of rilparencel to become a novel treatment option for patients with advanced CKD and diabetes," said Bruce Culleton, M.D., CEO ofProKidney

More than half of the approximately 360 patients required for the accelerated approval analysis using eGFR slope have been enrolled as of August 2025, with topline results anticipated in Q2 2027. The company ended the third quarter with $271.7 million in cash and marketable securities, supporting operations into mid-2027.

for any indication and remains the only product approved for children under age 12 with SR-aGvHD.announcedMesoblast LimitedRyoncilU.S. Food and Drug Administration

The flagship journalRyoncilMesoblastBlood

(ANP1) for sensorineural hearing loss and launched a new Type 1 Diabetes cell therapy initiative focused on large-scale islet cell production.third quarter 2025 financial resultsLineage Cell Therapeutics, Inc.OpRegenOPC1OpRegenRocheGenentechLineageWilliam Demant Invest A/SReSonance

"We entered into a research collaboration withWilliam Demant Invest A/SReSonanceLineage Cell TherapeuticsOpRegenOPC1

The company treated its first chronic spinal cord injury participant in the DOSED clinical study evaluatingOPC1California Institute for Regenerative MedicineLineage

by representatives of the ALS community requesting renewed regulatory review of data supporting NurOwn, which the company acknowledges as underscoring continued interest in the therapy's potential therapeutic value.BrainStorm Cell Therapeutics Inc.FDA

"We are making steady progress toward stabilizing our financial situation and initiating our Phase 3b study of NurOwn, designed to generate confirmatory data to support a potential BLA submission," said Chaim Lebovits, CEO ofBrainStorm Cell Therapeutics

The company reported cash and restricted cash of approximately $0.23 million as of September 30, 2025, with third quarter net loss of $2.1 million compared to $2.7 million in the prior year period. Research and development expenses decreased to $0.9 million from $1.0 million year-over-year, while general and administrative expenses declined from $2.0 million to $1.1 million.

https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors- need-to-know/Source:

CONTACT:

Equity Insider

info@equity-insider.com

(604) 265-2873

Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.DISCLAIMER:

SOURCES CITED:

1. https://media.market.us/global-cell-and-gene-therapy-manufacturing-market-news/

2. https://www.globenewswire.com/news-release/2025/11/21/3192705/28124/en/U-S-Cell-and-Gene-Therapy-CDMO-Market-Trends-Analysis-Report-2025-2033-Gene-CAR-T-Therapy-Boom-Drives-Demand-for-CDMO-Partnerships-and-Specialized-Manufacturing-Capacity.html

3. https://www.openpr.com/news/4307896/regenerative-medicine-market-2025-2033-key-trends-research

4. https://www.morningstar.com/news/pr-newswire/20251209ln42489/beyond-traditional-drugs-novel-platforms-targeting-hard-to-treat-conditions

Logo -https://mma.prnewswire.com/media/2840019/5684834/Equity_Insider_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/beyond-insulin-pumps-cell-therapies-unlock-a-403b-cure-economy-302643733.html